Impact of BMI on the Toxicity, Treatment Adherence, and Efficacy of Endocrine Therapy ± Palbociclib in Patients With Early HR+/HER2− Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
J. Clin. Oncol 2023 Aug 09;[EPub Ahead of Print], G Pfeiler, D Hlauschek, EL Mayer, C Deutschmann, S Kacerovsky-Strobl, M Martin, JL Meisel, N Zdenkowski, S Loibl, M Balic, H Park, A Prat, C Isaacs, E Bajetta, JM Balko, M Bellet-Ezquerra, J Bliss, H Burstein, F Cardoso, H Fohler, T Foukakis, KA Gelmon, M Goetz, TC Haddad, H Iwata, J Jassem, SC Lee, B Linderholm, M Los, EP Mamounas, KD Miller, PG Morris, E Munzone, EN Gal-Yam, A Ring, L Shepherd, C Singer, C Thomssen, LM Tseng, P Valagussa, EP Winer, AC Wolff, G Zoppoli, J Machacek-Link, C Schurmans, X Huang, E Gauthier, C Fesl, AC Dueck, A DeMichele, M GnantFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.